Phage display-derived peptides as therapeutic alternatives to antibodies

Drug Discovery Today

Volumn 9, Issue 12, 2004, Pages 525-529

  Ladner, Robert C ^a   Sato, Aaron K ^a   Gorzelany, Jennifer ^a   De Souza, Mark ^a  

^a Dyax Corp   (United States)

Author keywords

Biotechnology; drug candidate; Drug Discovery; Molecular Medicine; peptides; phage display

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; CANCER VACCINE; CARRIER PROTEIN; ENFUVIRTIDE; ENZYME INHIBITOR; EPTIFIBATIDE; GOSERELIN; HIRULOG; HUMAN INSULIN; INSULIN; INSULIN LISPRO; LEUPRORELIN; LISINOPRIL; NESIRITIDE; OCTREOTIDE; PEPTIDE; RECEPTOR BLOCKING AGENT; SALCATONIN; THROMBOPOIETIN; TUMOR ANTIGEN;

ACROMEGALY; AMINO ACID SEQUENCE; ANGINA PECTORIS; BINDING AFFINITY; BREAST CANCER; CONGESTIVE HEART FAILURE; ENDOMETRIOSIS; HUMAN; HYPERCALCEMIA; HYPERTENSION; NONHUMAN; OSTEOPOROSIS; PAGET BONE DISEASE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN TARGETING; REVIEW;

ANIMALS; ANTIBODIES; DRUG DESIGN; HUMANS; PEPTIDE LIBRARY; PEPTIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 2942560767     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03104-6     Document Type: Review

References (34)

1. Stockwin L., Holmes S. Antibodies as therapeutic agents: vive la renaissance! Expert Opin. Biol. Ther. 3:2003;1133-1152
2. Graff C.P., Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63:2003;1288-1296
3. Huang L., et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J. Biol. Chem. 278:2003;15532-15540
4. Franklin M.C., et al. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry. 42:2003;8223-8231
5. Volonterio A., et al. Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. Chemistry. 9:2003;4510-4522
6. Ashraf S.S., et al. Identification and characterization of peptide probes directed against PKCalpha conformations. J. Pept. Res. 61:2003;263-273
7. Hetian L., et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J. Biol. Chem. 277:2002;43137-43142
8. Karasseva N.G., et al. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J. Protein Chem. 21:2002;287-296
9. Fairbrother W.J., et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry. 37:1998;17754-17764
10. Fleming, T.J., et al. Discovery of high affinity peptide binders to BLyS by phage display. J. Mol. Recog. (in press)
11. Sato, A.K., et al. (2003) KDR and VEGF/KDR binding Peptides and their use in Diagnosis and Therapy. WO 03/074005. PCT/US03/06731
12. Arbogast, C., et al. (2003) Multivalent Constructs for Therapeutic and Diagnostic Applications. WO 03/084574. PCT/US03/06656
13. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct. 26:2001;25-35
14. Belizaire A.K., et al. Identification of a murine ICAM-1-specific peptide by subtractive phage library selection on cells. Biochem. Biophys. Res. Commun. 309:2003;625-630
15. Shannon J.P., et al. Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation. J. Pept. Res. 58:2001;140-150
16. Rao W.H., Camp R.D. Novel cyclic and linear oligopeptides that bind to integrin beta1 chain and either inhibit or costimulate T lymphocytes. Int. Immunopharmacol. 3:2003;435-443
17. Ulrichts H., et al. Selection of phages that inhibit vWF interaction with collagen under both static and flow conditions. Thromb. Haemost. 86:2001;630-635
18. Zhang J., et al. Identification of anti-TNFalpha peptides with consensus sequence. Biochem. Biophys. Res. Commun. 310:2003;1181-1187
19. El Zoeiby A., et al. Identification of novel inhibitors of Pseudomonas aeruginosa MurC enzyme derived from phage-displayed peptide libraries. J. Antimicrob. Chemother. 51:2003;531-543
20. Kazmin D.A., et al. Phage display mapping for peptide 11 sensitive sequences binding to laminin-1. J. Mol. Biol. 298:2000;431-445
21. Ide T., et al. Identification by the phage-display technique of peptides that bind to H7 flagellin of Escherichia coli. Biosci. Biotechnol. Biochem. 67:2003;1335-1341
22. Zobel K., et al. Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. Bioorg. Med. Chem. Lett. 13:2003;1513-1515
23. Dennis M.S., et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277:2002;35035-35043
24. Koehler M.F., et al. Albumin affinity tags increase peptide half-life in vivo. Bioorg. Med. Chem. Lett. 12:2002;2883-2886
25. de Serres M., et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells. 17:1999;203-209
26. Brinckerhoff L.H., et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J. Cancer. 83:1999;326-334
27. Yano A., et al. RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization. Vaccine. 22:2003;237-243
28. Torchilin V.P., Lukyanov A.N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today. 8:2003;259-266
29. Derossi D., et al. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8:1998;84-87
30. Drin G., et al. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci. 4:2002;26
31. Teskin R. It Lives for 29 Years? Legal Times. 26:2003;44
32. Roche Laboratories Inc., Trimeris I. About Fuzeon: Manufacturing. (Vol. 2004). 2003-2004
33. Lawless M.K., et al. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry. 35:1996;13697-13708
34. Coghill K. Trimeris, Roche Place Hold On T-1249; Trimeris Reduces Staff. BioWorld Today. 15:2004;1